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A kinetic study of the aqua substitution in the [TcO(OH2)(CN)4]
− complex by diﬀerent thiourea ligands (TU = thiourea, NMTU
= N-methyl thiourea, NNDMTU = N,N -dimethylthiourea) yielded second-order formation rate constants (25
◦C) as follows
[NNDMTU, NMTU, TU, respectively]: kf = 11.5 ± 0.1, 11.38 ± 0.04, and 7.4 ± 0.1 M
−1s−1, with activation parameters: ΔH#
kf :
55 ±2, 42 ±3, 35 ±5k Jm o l
−1; ΔS#
kf : −40 ±8, −84 ±11, −110 ±17 J K
−1mol
−1. A subsequent high-pressure investigation of the
aqua substitution in the [ReO(OH2)(CN)4]
− and [TcO(OH2)(CN4)]
− complexes by selected entering ligands yielded ΔV#
kf values
as follows: Re(V): −1.7 ± 0.3(NCS
−), −22.1 ± 0.9 (TU) and for Tc(V): −3.5 ± 0.3(NCS
−), −14 ± 1 (NNDMTU), and−6.0 ± 0.5
(TU)cm3mol
−1,respectively.TheseresultspointtoaninterchangeassociativemechanismforthenegativeNCS
− asenteringgroup
but even a pure associative mechanism for the neutral thiourea ligands.
Copyright © 2008 J. M. Botha and A. Roodt. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Technetium-99m is widely used in over 90% of all current
diagnostic nuclear medicinal applications [1–5]d u et oi t s
favourable nuclear properties (t1/2 = 6.02 hours, y =
140keV 100%) and availability from a generator. It is
routinely used for brain, heart, liver, kidney, and bone
imaging. Technetium’s third-row congener and 5d analog,
rhenium, also has applications in nuclear medicine since its
two radioactive isotopes, Re-186 and Re-188, have nuclear
properties suitable for radiotherapeutic applications [6–8].
The development of technetium myocardial imaging
agents commenced with work by Deutsch [9–12], who
investigated the [99mTcCl2(dmpe)2]+ [dmpe = bis(1,2-dim-
ethylphosphino)ethane] and [99mTcX2(diars)2]+ complexes
(diars = o-phenylenebis(dimethylarsine), X = Cl, Br) [12].
Studies on animal models indicated that the reduction of
Tc
III is biologically accessible for the cationic [99mTc
III−
Cl2(dmpe)2]+ complex, yielding neutral [99mTc
IICl2(dm-
pe)2]. The latter then washes from the heart and becomes
trapped in the liver. The reduction of ReIII to ReII [186ReIII−
Cl2(dmpe)2]+ is 0.2V more negative compared to the anal-
o g o u sT cc o m p l e xa n di st h u sr e t a i n e di nt h eh e a r t[ 10].
Kinetic, electrochemical, and structural work on the [Re/
Tc
IICl2(dmpe)2] complexes has been published and illus-
trates its importance as initial models [13–18].
Currently, however, other monocationic complexes of
technetium-99m are of signiﬁcant interest because of their
extensive use as 99mTc myocardial imaging agents [19,
20] with examples including Cardiolite or [99mTc(MIBI)6]+
(MIBI = 2-methoxy-2-methylpropylisocyanide) [21, 22]a n d
Myoview [99mTcO2(Tetrofosmin)2]+. While the monoca-
tioniccomplexesaretraditionallybasedonthe[O=Tc
V=O]+,
[Cl–Tc
III–Cl]+,a n dT c
I cores, a new class of myocardial
imaging agents feature the [99mTc
V≡N]
2+
core, an exam-
ple being the Tc–N–NOET complex (bis(N-methoxy-N-
methyldithiocarbamato)nitridotechnetium(V)).
Two technetium complexes, containing speciﬁcally phos-
phine ligands, currently used for myocardial imaging are the
above-mentioned Myoview and TechneScan Q12/TechneCard2 Metal-Based Drugs
([99mTc(PR3)2(L
 )]+)[23].In[99mTcO2(Tetrofosmin)2]+ the
technetium is in a high-oxidation state {Tc(V)} and shows
substantial myocardial uptake [24]. It is interesting to note
that [99mTcO2(dmpe)2]+, which has methyl groups on the
phosphine rather than the ether groups as in the tetrofosmin
ligand, is not retained in the myocardium [25].
With the ongoing development of new Tc and Re
agents, it is essential that their basic coordination chemistry
is understood. Nonradioactive rhenium is widely utilized
to imitate technetium chemistry on a macroscale and
has been extensively pursued for the past two decades
or more, describing changes in coordination modes. We
reported structural eﬀects induced by diﬀerent Re-cores
while maintaining an equatorial ligand set, utilizing two
dmpe ligands, while varying the axial core, to investigate the
impact this change induces on the solid-state structure of
the coordinated polyhedron and on the bidentate tertiary
phosphineligand,dmpe[26].Similarly,theeﬀectofdiﬀerent
conformers/isomers and energies associated therewith has
been described [27]. More recent extensive work by Alberto
showed that the fac-[(CO)3M(H2O)3]+ {M = Re(I), Tc(I)}
core provides excellent access to numbers of model radio-
pharmaceuticals [28–35].
The “lanthanide contraction” results in similar physical
characteristics for analogous Re and Tc complexes (i.e.,
size or lipophilicity) [1, 6]. Thus, when rhenium is used
as the nonradioactive surrogate for the development of Tc
chemistry because it is nonradioactive, their similar physical
characteristics make it very diﬃcult for biological systems
to distinguish between analogous Tc and Re [6]c o m p l e x e s
basedonpropertiessuchassize,shape,andcharge.However,
ﬁrstly, they diﬀer signiﬁcantly in their redox properties,
which can result in diﬀerent in vivo handling of analogous
complexes. Rhenium complexes are more stable in higher-
o x i d a t i o ns t a t e sa n dt h u sa r em o r ed i ﬃcult to reduce (by ca.
200mV) than their Tc analogs [36]. Thus, Re is more readily
reoxidized to perrhenate (ReO4
−) than Tc is to pertechnetate
(TcO4
−)i nv i v o , and perrhenate requires the use of stronger
reducingagentsforthesynthesisofReradiopharmaceuticals.
As e c o n dd i ﬀerence is the larger ligand ﬁeld splitting for
Re complexes, which results in slower-ligand substitution
onto Re than Tc. We have previously investigated diﬀerent
aspects of the trans-dioxo complexes, with the general
structureoftrans-[MO2(L4)]
n−,M=Mo(IV),W(IV),Tc(V),
Re(V), Os(VI), and related systems, evaluating structural
and reactivity correlations for a range of ligands L. It was
shown that a twelve-order of magnitude in reactivity in
these systems exists, ranging from the very rapid proton
exchange, to the slower hydroxo and aqua substitution and
the extremely slow-equatorial ligand substitution [37–41].
Subsequent kinetic studies on the [ReO(OH2)(TU)4]3+
complex, showed that the trans-substitution reactions of
the aqua ligand most likely proceed via an interchange
dissociative mechanism (Id)[ 42]. This outlined a discrep-
ancy in the proposed mechanism for trans-substitution
reactions on the [ReO(OH2)(CN)4)− complex as concluded
earlier in the literature [43, 44]. The substitution rate
for the [ReO(OH2)(TU)4]3+ complex with NCS− was
in the order of ca. 450000 times faster than for the
[ReO(OH2)(CN)4]− complex. Furthermore, the reactions
involving [ReO(OH2)(TU)4]3+ and higher concentrations of
the entering ligand showed typical limiting kinetics, while
in the [ReO(OH2)(CN)4]− complex, no tendency of limiting
kinetics was observed.
We have previously correlated diﬀerent in vivo reactiv-
ities with in vitro behaviour [41] and attempted to link
certain sites with biodistribution and bioactivity, but was,
and still is, unable to do more detailed comparisons. Thus,
since detailed mechanistic studies and data on substitution
processes are fairly limited, it prompted us to reinvestigate
the type of mechanism obeyed for the [ReO(OH2)(CN)4]−
complex when reacted with diﬀerent entering ligands and
extending it to the Tc
V complex, by speciﬁcally utilizing
advanced high-pressure kinetics. This high-pressure study
of the [MO(OH2)(CN)4]− complex (M = Re and Tc), with
diﬀerent entering ligands, is therefore reported here.
2. MATERIAL AND METHODS
All reagents and chemicals were of analytical reagent grade,
and double-distilled water was used in all experiments.
A l lp Hm e a s u r e m e n t sw e r ed o n ew i t ha nO r i o n7 0 1p H
meter and a combined glass/calomel electrode using stan-
dard buﬀer solutions and standardized hydrochloric acid
solutions for calibration. The ionic strength was constant
(μ = 1M) in all the experiments, maintained with NaNO3
as noncoordinating electrolyte. In all calculations, pH =
−log [H+]. Na3[ReO2(CN)4]a n dN a 3[TcO2(CN)4]w e r e
prepared as previously described [37]. Caution: Technetium-
99,althoughalow-energeticradio-activeβ-emitter(230KeV,
t1/2 = 2.1 × 105y), should always be handled with care and
under approved conditions.
Kinetic measurements were done on modiﬁed Durrum-
Gibson Model D110 and Applied Photophysics SX.18MV
(control experiments; coupled with a J&M Tidas-16 diode
array) stopped ﬂow spectrophotometers equipped with con-
stant temperature syringe and cell holder systems (accurate
within0.1◦C).Thesewerecoupledtoapersonalcomputeror
Acorn Risc workstation capable of performing least-squares
analyses on the absorption values versus time data obtained
from the kinetic runs. The SCIENTIST [45]p r o g r a mw a s
used to ﬁt the data to selected functions. High-pressure
studies were done on a GBC 916 spectrophotometer in
a high-pressure vessel with pill box cells of path length
≈15mm or in a stopped ﬂow high-pressure vessel [46].
All kinetic runs were performed under pseudo-ﬁrst-order
conditions with the ligand in large excess. The solid lines
in the ﬁgures represent computer least-squares ﬁts of data,
while the experimentally determined values are given as
points. The [MO(L)(CN)4]
n+ complexes from the reactions
between [MO(OH2)(CN)4]− and diﬀerent entering ligands
were characterised as previously described [43, 44].
3. RESULTS AND DISCUSSION
It was previously shown that the complete reaction scheme
governingthesubstitutionreactionsontheprotonatedforms
of the trans-[MO2(CN)4]
(n+2)
−
complexes is limited to theJ. M. Botha and A. Roodt 3
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Scheme 1: Illustration of an associative (A; k1/k2)o ra s s o c i a t i v e
interchange (B; k3/k4). Activation for the aqua substitution in
[MO(OH2)(CN)4]−[M = Re(V), Tc(V)]; RDS = rate determining
step.
aquaspecies,trans-[MO(OH2)(CN)4]
n− andwithsmallcon-
tributions, under selected conditions from trans-[MO(OH)-
(CN)4]
(n+1)
−
[37]. Assumptions made and approximations
have all been reported previously.
The pKa1 value (of the [TcO(OH2)(CN)4]− complex,
Scheme 1) was previously determined from the reaction
between [TcO(OH2)(CN)4]− and NCS− ions as 2.90(5) by
Roodt et al. [44]. To further verify this by another ligand
system, an independent kinetic pKa determination was
carried out for the reaction between [TcO(OH2)(CN)4]−
and NNDMTU and is illustrated in Figure 1. NNDMTU was
selected since these reactions showed the largest absorbance
changes.
The general expression for the observed pseudo-ﬁrst-
order rate constant {[L]   [M]} shown in (1), as obtained
previously, describes the acid-base behaviour of the trans-
[MO(OH2)(CN)4]
n− complexes, where kf and kr represent
the forward and reverse rate constants, that is, the ana-
tion/ligation and acid hydrolysis, respectively.
kobsd =
kf[L]
1+Ka1/

H+ = kr. (1)
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Figure 1: Plot of kobsd versus pH for the reaction between
[TcO(OH2)(CN)4]− and NNDMTU at 24.8◦C, μ = 1.0M
(NaNO3),[NNDMTU] =0.3M,and[M]=5×10
−5 M,λ = 420nm.
The data in Figure 1 was ﬁtted to (1), and a pKa1 value
as reported in Table 1 was obtained. The acid dissocia-
tion constant thus determined from the reaction between
[TcO(OH2)(CN)4]− and NNDMTU {2.99±0.19} is in good
agreement with the pKa value reported for the reaction
between the metal complex and NCS− ions (2.90 ± 0.05)
[44].
It is therefore evident that if the reaction between
[TcO(OH2)(CN)4]− and the diﬀerent entering ligands (TU,
NMTU, NNDMTU) is investigated at a pH value of 0.6
[pKa1 > 2.9, see Table 1], the trans-oxo aqua species of the
metalcomplexismorethan99%presentinsolution.Atthese
high-acidic conditions where Ka1   [H+], (1) simpliﬁes to
thewell-knownsimpleexpressionin(2),assumingnegligible
reverse or concurrent reactions (kr ca. 0). The kobsd versus
[L]dataobtainedfromtheserunswasﬁttedto(2),andvalues
for kf and kr were consequently obtained (Table 1):
kobsd = kf[L]+kr ≈ kf[L]. (2)
Theligandconcentrationandtemperaturedependencestudy
for each of the diﬀerent thiourea entering ligands (TU,
NMTU, and NNDMTU) were therefore completed for the
[TcO(OH2)(CN)4]−, with the data for NMTU as entering
ligand shown in Figure 2.
These kf versus temperature data sets were used in the
Eyring equation [43] to calculate the activation parameters
governing the kf step (Table 1). The intercepts (kr)i n
all these runs were zero within standard deviations, thus
conﬁrming a large Kf value (Kf = kf/kr) for each of the
diﬀerent nucleophiles.
The activation entropies (Table 1) for all the reactions
studied suggest increased order in the transition state,
indicative of association being important.
Following similar arguments used by Grundler et al.
[35], and by our group [47], diﬀerent pathways for the
substitution process were therefore considered.4 Metal-Based Drugs
Table 1: Kinetic data for the reaction between [TcO(OH2)(CN)4]− and the diﬀerent thiourea entering ligands; μ = 1.0M(N aNO 3), pH =
0.6. (a)L.S. ﬁts to (2); (b)since small-negative intercepts were obtained in some cases, the value was ﬁxed (= 0.00). The standard deviations
reported are those from the ﬁrst ﬁts; (c)L.S. ﬁts to (1).
Parameter T (◦C) NNDMTU T (◦C) NMTU T (◦C) TU
kf(M−1s−1)
(a) 9.3 3.13(6) 5.7 3.26(7) 6.8 2.68(8)
16.5 6.1(1) 15.9 5.95(6) 15.8 5.0(1)
25.1 11.5(1) 25.1 11.38(4) 25.5 7.4(1)
kr(s−1)
(a), (b) 9.3 0.00(1) 5.7 0.00(3) 6.8 0.00(2)
16.5 0.00(4) 15.9 0.00(5) 15.8 0.00(3)
25.1 0.00(3) 25.1 0.00(2) 25.5 0.06(2)
pKa1
(c) 24.8 2.99(19) — — — —
ΔS
#
kf (JK−1 mol−1)— −40(8) — −84(11) — −110(17)
ΔH
#
kf (kJ mol−1) — 55(2) — 42(3) — 35(5)
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Figure 2: Eﬀect of kobsd versus [NMTU] for the reaction between
[TcO(OH2)(CN)4]− and NMTU at diﬀerent temperatures, μ =
1.0M(N aNO 3), λ = 420nm, pH = 0.6, and [M] = 5 ×10
−5 M.
Firstly, for an associative mechanism (Scheme 1, A, k1
and k2 pathway), the rate of the reaction is given by
Rate = k2[MO(OH2)(L)(CN)4
n−] − k−2[MO(L)(CN)4
m−].
(3)
If it is assumed that the [MO(OH2)(L)(CN)4]
n complex
is formed under steady-state conditions, its formation and
decomposition would be equal yielding

MO(OH2)(L)(CN)4
n−
=
k1

MO(OH2)(CN)4
−
[L] + k−2

MO(L)(CN)4
m−
k−1 +k2
.
(4)
Upon incorporation of the deﬁnition of Ka1 (= [MO(OH)
(CN)4
2−][H+]/[MO(OH2)(CN4
−)]), [M]tot (= [MO(OH2)
(CN)4
−] + [MO(OH)(CN)4
2−]) and substituting (4) into
(3), integration of the rate law {[L]   [M]}, by assuming
af a s tk2 step (Scheme 1), 5 {with k2
  = k1k2/(k−1+k2)},a n d
deﬁning the pseudo-ﬁrst-order rate constant, is obtained:
kobsd =
k2
 [L]
1+Ka1/

H+ +k−2. (5)
Similar arguments may be used, considering an interchange
pathway (Scheme 1, k3 and k4), incorporating the deﬁnition
of Ka1 (= [MO(OH)(CN)4
2−][H+]/[MO(OH2)(CN)4
−]),
[M]tot (= [MO(OH2)(CN)4
−] + [MO(OH)(CN)4
2−]+
[MO(OH2)(L)(CN)4
n−]), K3 (= [MO(OH2)(L)(CN)4
n−]
/[MO(OH2)(CN)4
−][L]; ([L]   [M]tot), yielding an expres-
sion for the pseudo-ﬁrst-order rate constant as given in (6),
and assuming K3[L]   1,
kobsd =
k4K3[L]
Ka1/

H+]+1
+k−4. (6)
It is clear that (5)a n d( 6) are similar and both adequately
describe the experimental results {associative mechanism
(5): kf = k2
  and kr = k−2; interchange mechanism (6): kf =
k4K3 and kr = k−4 and K3 = k3/k−3}, and both simplify to
(1)a n d( 2), respectively.
The pressure dependence for the substitution process as
studied here, at diﬀerent pressures a and b,i sg i v e nb y[ 47]
ln

ka/kb

=− ΔV#
expt.

Pa −Pb

/RT. (7)
Since the contribution by the reverse step is negligible in
all cases in this study as concluded above, this implies that
ΔV#
expt. ≈ ΔV#
kf . The data obtained for the trans-[TcO
(OH2)(CN)4]− are shown in Figure 3, where (7) was utilized
to obtain ΔV#
expt., and the results are reported in Table 1.
In order to compare the type of mechanism obeyed for
trans-aqua substitution in the [ReO(OH2)(CN)4]− complex,
a high pressure study with NCS− ions and TU was also
performed. Since the reaction between [ReO(OH2)(CN)4]−
and L (L = NCS− and TU) shows equilibrium constants
of 87 ± 7a n d7 .0 ± 0.4M −1,r e s p e c t i v e l y[ 48, 49], similar
arguments to the Tc(V) as mentioned above could be used
to determine the activation volume, ΔV#
expt., for which the
values are reported in Table 2.
This high pressure kinetic study on the reaction between
[TcO(OH2)(CN)4]− and NCS− ions, NNDMTU and TUJ. M. Botha and A. Roodt 5
Table 2: Comparative table for the kinetic data and activation parameters for the ligation reactions of [ReO(OH2)(CN)4]− and
[TcO(OH2)(CN)4]− at 25◦C. (a)Refrences [37, 48], (b)this work.
Parameter Metal NCS− NNDMTU NMTU TU HN3
kf (M−1 s−1)R e (a) 0.00348(4) 0.059(2) 0.067(2) 0.0399(9) 0.0064(2)
Tc(b) 22.2(3)(a) 11.5(4) 11.38(4) 7.4(1) —
kfTc/kfRe — 6321 195 170 185 —
ΔS
#
kf (JK−1 mol−1)R e (a) −11(6) −119(40) −125(10) −95(3) −87(6)
Tc(b) −9(12) −40(8) −84(11) −110(17) —
ΔH
#
kf (kJ mol−1)R e (a) 17.4(1.9) 45(11) 42(3) 52(1) 60(2)
Tc(b) 62(4) 55(2) 42(3) 35(5) —
ΔV
#
kf (cm3 mol−1)R e (b) −1.7(3) — — −22.1(9) —
Tc(b) −3.5(3) −14(1) — −6.0(5) —
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Figure 3: The eﬀect of pressure on the second-order formation
rate constant for the reaction between [TcO(OH2)(CN)4]− and
NCS−, NNDMTU, and TU at 25◦C, pH = 0.6, [M] = 5 × 10
−5 M,
λ = 420nm, a refers to left axis, b refers to the right axis. [NCS−] =
0.2M, [NNDMTU] = [TU] = 0.05M, μ = 1.0M (NaNO3).
[Figure 3], yields ΔV#
expt. values of −3.5 ± 0.3, −14 ± 1
and −6.0 ± 0.5cm 3/mol, respectively. Similarly, the data for
the Re(V), as represented in Figure 4 gave ΔV#
expt. values of
−1.7 ± 0.3a n d−22.1 ± 0.9cm 3/mol for NCS− ions and TU
respectively. It is clear that all these indicate small to large
negative values, contrary to the experiments on Alberto’s ReI
and Tc
I complexes [35].
We previously concluded that with regard to the mecha-
nism, due to the large distortion (metal displaced out of the
plane formed by the four cis ligands bonded to the metal,
away from the trans-oxo) observed for the [MO(L)(CN)4]n−
complexes of MoIV,W IV,R e V,a n dT c
V, a dissociative acti-
v a t i o nw o u l db ef a v o u r e dd u r i n gtrans-aqua substitution
reactions [44, 47]. A positive volume of activation (+10.6 ±
0.5cm 3/mol) was observed for the reaction between the
corresponding isostructural [WO(OH2)(CN)4]2− complex
and N3
−, forming an important basis of the mechanistic
assignment.
However, the current high-pressure study on the
[ReO(OH2)(CN)4]− and [TcO(OH2)(CN)4]− complexes
clearly indicates a negative volume of activation for all these
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Figure 4: The eﬀect of pressure on the second-order formation rate
for the reaction between [ReO(OH2)(CN)4]− and NCS− ions and
TU at 25◦C, pH = 0.3, [M] = 1.5 × 10
−3 M, a refers to left axis, b
refers to right axis. [NCS−] =0.6M, λNCS
− = 420nm; [TU] = 1.0 M,
λTU = 350nm, μ = 1.0M (NaNO3).
reactions (Table 2), ranging from slightly negative for the
anionicNCS− asenteringligand,tosubstantiallynegativefor
the neutral thiourea ligands. This yields important evidence,
along with the large negative ΔS# values, that an associative
(A)mechanismoranassociativeinterchange(Ia)mechanism
is operative for the activation step during these trans-aqua
substitution reactions on the M(V) metals. In principle, this
is actually quite acceptable, since the [MO(OH2)(CN)4]
n−
complexes of MoIV,W IV,R e V and Tc
V are all classic 16
electron species. Clearly, the M(IV) metal centres are
softer than the corresponding ReV and Tc
V, allowing easier
dissociation of the aqua ligand in the rate determining
step. This is conﬁrmed by the solid state structures of the
[MO(NCS)(CN)4]2− complexes, wherein both of the NCS−
ligands where nitrogen bound. [43, 44].
The formation of the [MO(L)(CN)4]
m− complex in
Scheme 1 in an A mechanism yields an activation volume
ΔV#
expt. = ΔV#
kf = ΔV#
k2
 ,w h i c hi se x p e c t e dt ob e
large negative, and holds true for the reactions between
both [ReO(OH2)(CN)4]− and TU (ΔV#
k2
 
=− 22.1
(9)c m 3 mol−1) and [TcO(OH2)(CN)4]− and NNDMTU6 Metal-Based Drugs
(ΔV#
kf =− 14(1)cm3 mol−1)andt oalessere xt endfor[TcO
(OH2)(CN)4]− and TU (ΔV#
kf =− 6.0 ± 0.5cm 3 mol−1).
It is therefore realistic that the neutral ligands will asso-
ciate more easily with the [MO(OH2)(CN)4]− species,
compared to association between two negative species
{[MO(OH2)(CN)4]− and the NCS− ligand}, supporting
the assumption of an associative process. Furthermore, the
reaction between [MO(OH2)(CN)4]− and NCS− yielded
activation values of −1.7 ± 0.3a n d−3.5 ± 0.3cm 3 mol−1
for ReV and Tc
V, respectively. These are considered too
smallnegativevaluestosupportapureassociativeactivation,
although electrostriction between the negatively charged
complex and entering NCS− ligand might aﬀect the total
value of ΔV#
expt..
For an Ia mechanism, the volume of activation can be
expressed as the sum of the individual contributions for each
step in Scheme 1 (8), where kf = k4K3 and ΔVK3 = reaction
volume for the equilibrium reaction deﬁned by K3:
ΔV#
expt. = ΔVK3 +ΔV#
k4. (8)
The k4 step is associated with a simultaneous bond break-
ing/formation process, and therefore ΔV#
k4 is expected to be
slightly negative in an interchange associative process. Fur-
thermore, ΔVK3 can be expressed in terms of its individual
components (9):
ΔVK3 = ΔV#
k3 −ΔV#
k−3. (9)
Since ΔV#
k−3 is expected to be positive (associated with
bond breaking), and ΔV#
k3 in turn is slightly negative, ΔVK3
is expected to be either small positive or slightly negative.
It is thus clear from (9), that depending on the relative
magnitude of the volume change associated with K3 and
k4, that either an Id or Ia mechanism is possible. However,
since an overall negative tendency for ΔV#
expt. was obtained,
an associative interchange mechanism is considered more
likelyfortheNCS− reaction,sincethereshouldbesigniﬁcant
electrostriction between the NCS− and [M]− species. For the
neutral thiourea ligands, an even larger-negative activation
volumeisobserved,andapureassociativemodeofactivation
could well be operative.
Upon comparison of the trans-substitution reactions on
the[ReO(OH2)(CN)4]− and[TcO(OH2)(CN)4]− complexes
(Table 2), a few other interesting observations are also made.
Firstly, for the [ReO(OH2)(CN)4]− complex, the order
of reactivity for the ligands are: NMTU > NNDMTU > TU
> NCS− > HN3 and for the [TcO(OH2)(CN)4]− complex:
NCS− > NNDMTU > NMTU > TU. It is clear that the NCS−
ligand shows the fastest reaction with the Tc centre (ca. 6300
times faster), but the slowest reaction with the Re centre [see
relative ratio’s of kfTc/kfRe in Table 2]. A comprehensive
explanation of this rate diﬀerence is not yet possible. It is,
however, known that the Tc
V centre can more readily accept
electron density than does the ReV [50, 51]a n dt os o m e
extend favour, in spite of the negative charge on the NCS−
as entering ligand, association with the Tc
V centre. This
is, however, not manifested in the activation volumes. The
rate constants of the thiourea ligands are more comparable,
Table 3:Comparisonbetween pKa valuesofmethylsubstitutedand
unsubstituted compounds [52].
Compound pKa1 Compound pKa1
Cinnamic acid 4.44 P-Methylcinnamic acid 4.56
Malonic acid 2.83 Methylmalonic acid 3.07
Acetic acid 4.75 Trimethylacetic acid 5.03
Pyridine 5.25 2,4-Dimethylpyridine 6.57
Methylamine 10.66 Dimethylamine 10.73
showing a great deal of consistency for both metal centres,
although a slight dependence on steric bulk/electron density
of the TU ligands is apparent, but cannot currently be
convincingly explained, see below.
Secondly, since it is known that methyl substituents on a
ligand can increase the pKa value and therefore the electron
donating ability thereof (see examples in Table 3 [52]), it
is expected in an associative mechanism that the methyl
substituted thiourea will react slightly faster than TU, as was
concluded from this work on the ReV system.
Thirdly,the[MO(OH2)(CN)4]
n− compoundsofTc
V and
ReV react both according to an associative mechanism or
partly associative, while the MoIV and WIV compounds react
via a dissociative mechanism. From this, it is clear that the
work done on the MoIV and WIV centres, although all iso-
structural d2 species, cannot be applied directly to the Tc
V
and ReV centres, as assumed previously [13]. It also implies
that the higher-oxidation state of the Tc
V and ReV centres
favour the more associative activation, while the MoIV and
WIV could favour a dissociative activation mode.
However, even more detailed high-pressure studies,
to enable construction of complete volume proﬁles, are
required in future.
These results, along with the fact that the Tc(V) centre
is much more reactive than the Re(V), is of particular
relevance to nuclear medicine. In the preparation of 99mTc
radiopharmaceuticals or in the labelling of antibodies with
99mTc, “transfer” ligands are often used to stabilize the
required oxidation state, and then the actual labelling
is accomplished by simple ligand substitution onto the
“transfer complex” [53]. From this work, the best way of
optimizing labelling conditions would be to use a S-donor
transfer ligand instead of a C- or N-donor transfer ligand so
that the exchange process would be dissociative in nature.
This would imply that the transfer ligand, rather than the
concentration of the antibody or chelating moiety attached
to the antibody, would inﬂuence the reaction rate and
yield a much “cleaner” reaction mixture (concentration of
unlabeled antibody in solution would be low). Furthermore,
the greater reactivity of Tc compared to Re must be taken
into account when developing therapeutic radio-rhenium
analogues to known diagnostic 99mTc radiopharmaceuticals.
For example, more drastic conditions are required in the
preparation of 186Re diphosphonates (for bone imaging)
than in the preparation of 99mTc diphosphonates [54]. These
diﬀerences in reactivities between Tc
V and ReV centres
needs to be taken into account before procedures that areJ. M. Botha and A. Roodt 7
available for certain technetium complexes are applied to the
preparation of the rhenium analogues.
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